JBIO JADE BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, JADE BIOSCIENCES INC reported revenue of n/a, net income of −$55.8M and diluted EPS of −$0.76; for the fiscal year ended December 2025 revenue was n/a.
JBIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$114M, net income −$127M (margin n/a), EPS −$3.19
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$74.6M, net income −$69.6M (margin n/a), EPS −$2.44
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$81.4M, net income −$75.5M (margin n/a), EPS −$2.87
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$53.2M, net income −$51.5M (margin n/a), EPS −$2.10
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$23.0M, net income −$23.0M (margin n/a), EPS −$1.87
JBIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$55.8M, EPS −$0.76
- Quarter ended Mar 31, 2026: revenue n/a, net income −$40.4M, EPS −$0.57
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$31.9M, EPS $10.25
- Quarter ended Sep 30, 2025: revenue n/a, net income −$25.2M, EPS −$0.48
- Quarter ended Jun 30, 2025: revenue n/a, net income −$32.1M, EPS −$0.86
- Quarter ended Mar 31, 2025: revenue n/a, net income −$38.2M, EPS −$12.10
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$5.39M, EPS $4.41
- Quarter ended Sep 30, 2024: revenue n/a, net income −$16.3M, EPS −$5.16
- Quarter ended Jun 30, 2024: revenue n/a, net income −$24.8M, EPS −$0.86
- Quarter ended Mar 31, 2024: revenue n/a, net income −$23.2M, EPS −$0.83
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$20.4M, EPS −$0.73
- Quarter ended Sep 30, 2023: revenue n/a, net income −$19.6M, EPS −$0.71
- Quarter ended Jun 30, 2023: revenue n/a, net income −$19.0M, EPS −$0.76
- Quarter ended Mar 31, 2023: revenue n/a, net income −$16.5M, EPS −$0.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$15.0M, EPS −$0.60
- Quarter ended Sep 30, 2022: revenue n/a, net income −$13.6M, EPS −$0.56
- Quarter ended Jun 30, 2022: revenue n/a, net income −$12.0M, EPS −$0.49
- Quarter ended Mar 31, 2022: revenue n/a, net income −$10.9M, EPS −$0.45
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$8.22M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$6.18M, EPS −$0.26
JBIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$94.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$71.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$56.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$39.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$27.4M, share buybacks n/a
JBIO balance sheet
- Jun 30, 2026: cash $107M, total assets $472M, total liabilities $32.2M, shareholders' equity $440M
- Mar 31, 2026: cash $55.1M, total assets $319M, total liabilities $23.0M, shareholders' equity $296M
- Dec 31, 2025: cash $88.4M, total assets $350M, total liabilities $17.3M, shareholders' equity $333M
- Sep 30, 2025: cash $50.1M, total assets $202M, total liabilities $23.1M, shareholders' equity $179M
- Jun 30, 2025: cash $221M, total assets $224M, total liabilities $22.4M, shareholders' equity $202M
- Mar 31, 2025: cash $44.2M, total assets $77.5M, total liabilities $2.49M, shareholders' equity −$83.5M
- Dec 31, 2024: cash $69.4M, total assets $72.8M, total liabilities $120M, shareholders' equity −$46.8M
- Sep 30, 2024: cash $31.1M, total assets $91.0M, total liabilities $10.5M, shareholders' equity −$16.9M
Is JBIO profitable?
No. JADE BIOSCIENCES INC lost $153M over the last four quarters.
What is JBIO's EPS?
Diluted earnings per share over the last four quarters were $8.44; −$0.76 in the latest quarter.